Georgia is currently home to 1948 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
NCT06151197
Recruiting
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Endo Site 24, Lawrenceville, Georgia
Conditions: Plantar Fibromatosis, Ledderhose Disease
Register for Updates
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Research Site 111, Atlanta, Georgia
Conditions: Advanced Solid Tumor
Register for Updates
Mindfulness in Chronic Kidney Disease
NCT04099992
Recruiting
This study will test whether mindfulness meditation (MM) improves sympathetic function in chronic kidney disease (CKD) and whether transcutaneous vagus nerve stimulation (tVNS) optimizes the sympatho-inhibitory effects of mindfulness meditation (MM) and restores autonomic balance in CKD patients.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/03/2025
Locations: Atlanta VA Medical Center, Atlanta, Georgia
Conditions: Chronic Kidney Diseases
Register for Updates
Neurovascular Transduction During Exercise in Chronic Kidney Disease
NCT02947750
Recruiting
The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/03/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia
Conditions: Renal Insufficiency, Chronic
Register for Updates
Sympatholysis in Chronic Kidney Disease
NCT02411773
Recruiting
The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/03/2025
Locations: Atlanta VA Medical Center, Decatur, Georgia
Conditions: Chronic Kidney Disease
Register for Updates
Sympathetic Overactivity in Post-traumatic Stress Disorder
NCT01627301
Recruiting
Post-traumatic stress disorder (PTSD) is a highly prevalent anxiety disorder that is associated with an increased risk of cardiovascular (CV) disease and hypertension. One potential mechanism is overactivation of the sympathetic nervous system (SNS), both at rest and particularly during stress. This study will evaluate whether 8 weeks of daily DGB therapy or transcutaneous vagus nerve stimulation (tVNS) therapy improves SNS activity at rest and during stress.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Atlanta VA Medical Center, Decatur, Georgia
Conditions: Post-traumatic Stress Disorder, Prehypertension
Register for Updates
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618
Recruiting
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
03/01/2025
Locations: Georgia Nephrology Research Inst, Lawrenceville, Georgia
Conditions: C3G
Register for Updates
A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
NCT06290401
Recruiting
The goal of this clinical trial is to evaluate the impact of SCThrive (a behavioral self-management intervention) on patient activation, self-management behaviors, daily functioning, and emergency room visits in 260 adolescents and young adults with sickle cell disease (SCD) ages 13-21 receiving care at 1 of 4 pediatric SCD clinics. The main question\[s\]it aims to answer are: * Does SCThrive improve patient activation? * Does SCThrive improve self-management behaviors, daily functioning, and... Read More
Gender:
ALL
Ages:
Between 13 years and 21 years
Trial Updated:
02/28/2025
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Anemia, Sickle Cell
Register for Updates
Direct-to-patient Teledermatology and Computer-assisted Diagnosis
NCT05128006
Recruiting
This study will examine access to dermatology care. The operational partner will implement a direct-to-new patient teledermatology clinical care pathway while the research will study the effects of that implementation, use data associated with deployment to develop and test an Artificial Intelligence system, and understand key stakeholders' attitudes regarding and readiness for remote dermatology care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia
Conditions: New Patient Use of Teledermatology Mobile App
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Augusta, Georgia
Conditions: Neoplasms
Register for Updates
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591
Recruiting
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
02/27/2025
Locations: Vanda Investigational Site, Atlanta, Georgia
Conditions: Schizophrenia, Bipolar I Disorder
Register for Updates
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
NCT05487170
Recruiting
This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL). This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Emory University Winship Cancer Institute, Atlanta, Georgia
Conditions: Advanced Solid Tumor, DLBCL
Register for Updates